{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T05:49:04Z","timestamp":1773294544608,"version":"3.50.1"},"reference-count":65,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2007,8,16]],"date-time":"2007-08-16T00:00:00Z","timestamp":1187222400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/2.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["BMC Psychiatry"],"published-print":{"date-parts":[[2007,12]]},"DOI":"10.1186\/1471-244x-7-40","type":"journal-article","created":{"date-parts":[[2007,8,16]],"date-time":"2007-08-16T18:13:53Z","timestamp":1187288033000},"source":"Crossref","is-referenced-by-count":61,"title":["Atypical antipsychotics in bipolar disorder: systematic review of randomised trials"],"prefix":"10.1186","volume":"7","author":[{"given":"Sheena","family":"Derry","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R Andrew","family":"Moore","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2007,8,16]]},"reference":[{"key":"227_CR1","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1176\/appi.ajp.163.2.177","volume":"163","author":"AC Swann","year":"2006","unstructured":"Swann AC: What is bipolar disorder?. Am J Psychiatry. 2006, 163: 177-179. 10.1176\/appi.ajp.163.2.177.","journal-title":"Am J Psychiatry"},{"key":"227_CR2","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1177\/070674370605100104","volume":"51","author":"A Schaffer","year":"2006","unstructured":"Schaffer A, Cairney J, Cheung A, Veldhuizen S, Levitt A: Community survey of bipolar disorder in Canada: lifetime prevalence and illness characteristics. Can J Psychiatry. 2006, 51: 9-16.","journal-title":"Can J Psychiatry"},{"key":"227_CR3","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.4088\/JCP.v66n1001","volume":"66","author":"BF Grant","year":"2005","unstructured":"Grant BF, Stinson FS, Hasin DS, Dawson DA, Chou SP, Ruan WJ, Huang B: Prevalence, correlates, and comorbidity of bipolar I disorder and axis I and II disorders: results from the National Epidemiologic Survey on Alcohol and Related Conditions. J Clin Psychiatry. 2005, 66: 1205-1215.","journal-title":"J Clin Psychiatry"},{"key":"227_CR4","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1176\/appi.ajp.163.2.217","volume":"163","author":"RH Perlis","year":"2006","unstructured":"Perlis RH, Ostacher MJ, Patel JK, Marangell LB, Zhang H, Wisniewski SR, Ketter TA, Miklowitz DJ, Otto MW, Gyulai L, Reilly-Harrington NA, Nierenberg AA, Sachs GS, Thase ME: Predictors of recurrence in bipolar disorder: primary outcomes from the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD). Am J Psychiatry. 2006, 163: 217-224. 10.1176\/appi.ajp.163.2.217.","journal-title":"Am J Psychiatry"},{"key":"227_CR5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta7010","volume":"7","author":"AM Bagnall","year":"2003","unstructured":"Bagnall AM, Jones L, Ginnelly L, Lewis R, Glanville J, Gilbody S, Davies L, Torgerson D, Kleijnen J: A systematic review of atypical antipsychotic drugs in schizophrenia. Health Technol Assess. 2003, 7: 1-193.","journal-title":"Health Technol Assess"},{"key":"227_CR6","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1136\/bmj.38125.465579.55","volume":"329","author":"PE Lee","year":"2004","unstructured":"Lee PE, Gill SS, Freedman M, Bronskill SE, Hillmer MP, Rochon PA: Atypical antipsychotic drugs in the treatment of behavioural and psychological symptoms of dementia: systematic review. BMJ. 2004, 329: 75-10.1136\/bmj.38125.465579.55.","journal-title":"BMJ"},{"key":"227_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/0197-2456(95)00134-4","volume":"17","author":"AR Jadad","year":"1996","unstructured":"Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, McQuay HJ: Assessing the quality of reports of randomized clinical trials: is blinding necessary?. Control Clin Trials. 1996, 17: 1-12. 10.1016\/0197-2456(95)00134-4.","journal-title":"Control Clin Trials"},{"key":"227_CR8","doi-asserted-by":"publisher","first-page":"1896","DOI":"10.1016\/S0140-6736(99)04149-5","volume":"354","author":"D Moher","year":"1999","unstructured":"Moher D, Cook DJ, Eastwood S, Olkin I, Rennie D, Stroup DF: Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Quality of Reporting of Meta-analyses. Lancet. 1999, 354: 1896-1900. 10.1016\/S0140-6736(99)04149-5.","journal-title":"Lancet"},{"key":"227_CR9","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/S0304-3959(98)00140-7","volume":"78","author":"RA Moore","year":"1998","unstructured":"Moore RA, Gavaghan D, Tramer MR, Collins SL, McQuay HJ: Size is everything \u2013 large amounts of information are needed to overcome random effects in estimating direction and magnitude of treatment effects. Pain. 1998, 78: 209-216. 10.1016\/S0304-3959(98)00140-7.","journal-title":"Pain"},{"key":"227_CR10","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/S0304-3959(99)00302-4","volume":"85","author":"DJ Gavaghan","year":"2000","unstructured":"Gavaghan DJ, Moore RA, McQuay HJ: An evaluation of homogeneity tests in meta-analyses in pain using simulations of individual patient data. Pain. 2000, 85: 415-424. 10.1016\/S0304-3959(99)00302-4.","journal-title":"Pain"},{"key":"227_CR11","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1016\/S0895-4356(00)00242-0","volume":"53","author":"JA Sterne","year":"2000","unstructured":"Sterne JA, Gavaghan D, Egger M: Publication and related bias in meta-analysis: power of statistical tests and prevalence in the literature. J Clin Epidemiol. 2000, 53: 1119-1129. 10.1016\/S0895-4356(00)00242-0.","journal-title":"J Clin Epidemiol"},{"key":"227_CR12","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1016\/j.jclinepi.2005.01.006","volume":"58","author":"N Terrin","year":"2005","unstructured":"Terrin N, Schmid CH, Lau J: In an empirical evaluation of the funnel plot, researchers could not visually identify publication bias. J Clin Epidemiol. 2005, 58: 894-901. 10.1016\/j.jclinepi.2005.01.006.","journal-title":"J Clin Epidemiol"},{"key":"227_CR13","doi-asserted-by":"publisher","first-page":"224","DOI":"10.7326\/0003-4819-107-2-224","volume":"107","author":"KA L'Abbe","year":"1987","unstructured":"L'Abbe KA, Detsky AS, O'Rourke K: Meta-analysis in clinical research. Ann Intern Med. 1987, 107: 224-233.","journal-title":"Ann Intern Med"},{"key":"227_CR14","first-page":"50","volume-title":"Statistics with confidence \u2013 confidence intervals and statistical guidelines","author":"JA Morris","year":"1995","unstructured":"Morris JA, Gardner MJ: Calculating confidence intervals for relative risk, odds ratios and standardised ratios and rates. Statistics with confidence \u2013 confidence intervals and statistical guidelines. Edited by: Gardner MJ, Altman DG. 1995, London: British Medical Journal, 50-63."},{"key":"227_CR15","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1136\/bmj.310.6977.452","volume":"310","author":"RJ Cook","year":"1995","unstructured":"Cook RJ, Sackett DL: The number needed to treat: a clinically useful measure of treatment effect. BMJ. 1995, 310: 452-454.","journal-title":"BMJ"},{"key":"227_CR16","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1136\/bmj.315.7109.635","volume":"315","author":"MR Tram\u00e8r","year":"1997","unstructured":"Tram\u00e8r MR, Reynolds DJM, Moore RA, McQuay HJ: Impact of covert duplicate publication on meta-analysis: a case study. British Medical Journal. 1997, 315: 635-9.","journal-title":"British Medical Journal"},{"key":"227_CR17","doi-asserted-by":"publisher","first-page":"R644","DOI":"10.1186\/ar1704","volume":"7","author":"RA Moore","year":"2005","unstructured":"Moore RA, Derry S, Makinson GT, McQuay HJ: Tolerability and adverse events in clinical trials of celecoxib in osteoarthritis and rheumatoid arthritis: systematic review and meta-analysis of information from company clinical trial reports. Arthritis Res Ther. 2005, 7: R644-65. 10.1186\/ar1704.","journal-title":"Arthritis Res Ther"},{"key":"227_CR18","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1001\/archpsyc.60.11.1079","volume":"60","author":"M Tohen","year":"2003","unstructured":"Tohen M, Vieta E, Calabrese J, Ketter TA, Sachs G, Bowden C, Mitchell PB, Centorrino F, Risser R, Baker RW, et al: Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression. Arch Gen Psychiatry. 2003, 60: 1079-1088. 10.1001\/archpsyc.60.11.1079.","journal-title":"Arch Gen Psychiatry"},{"key":"227_CR19","doi-asserted-by":"publisher","first-page":"1715","DOI":"10.4088\/JCP.v65n1218","volume":"65","author":"RC Shelton","year":"2004","unstructured":"Shelton RC, Stahl SM: Risperidone and paroxetine given singly and in combination for bipolar depression. J Clin Psychiatry. 2004, 65: 1715-1719.","journal-title":"J Clin Psychiatry"},{"key":"227_CR20","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1176\/appi.ajp.162.7.1351","volume":"162","author":"JR Calabrese","year":"2005","unstructured":"Calabrese JR, Keck PE, Macfadden W, Minkwitz M, Ketter TA, Weisler RH, Cutler AJ, McCoy R, Wilson E, Mullen J: A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression. Am J Psychiatry. 2005, 162: 1351-1360. 10.1176\/appi.ajp.162.7.1351.","journal-title":"Am J Psychiatry"},{"key":"227_CR21","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.4088\/JCP.v67n0703","volume":"67","author":"EB Brown","year":"2006","unstructured":"Brown EB, McElroy SL, Keck PE, Deldar A, Adams DH, Tohen M, Williamson DJ: A 7-week, randomized, double-blind trial of olanzapine\/fluoxetine combination versus lamotrigine in the treatment of bipolar I depression. J Clin Psychiatry. 2006, 67: 1025-1033.","journal-title":"J Clin Psychiatry"},{"key":"227_CR22","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1097\/01.jcp.0000248603.76231.b7","volume":"26","author":"ME Thase","year":"2006","unstructured":"Thase ME, Macfadden W, Weisler RH, Chang W, Paulsson B, Khan A, Calabrese JR, BOLDER II Study Group: Efficacy of quetiapine monotherapy in bipolar I and II depression: a double-blind, placebo-controlled study (the BOLDER II study). J Clin Psychopharmacol. 2006, 26: 600-609. 10.1097\/01.jcp.0000248603.76231.b7.","journal-title":"J Clin Psychopharmacol"},{"key":"227_CR23","first-page":"176","volume":"21","author":"J Segal","year":"1998","unstructured":"Segal J, Berk M, Brook S: Risperidone compared with both lithium and haloperidol in mania: a double-blind, randomized controlled trial. Clin Neuropharmacol. 1998, 21: 176-180.","journal-title":"Clin Neuropharmacol"},{"key":"227_CR24","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1176\/ajp.156.5.702","volume":"156","author":"M Tohen","year":"1999","unstructured":"Tohen M, Sanger TM, McElroy SL, Tollefson GD, Chengappa KN, Daniel DG, Petty F, Centorrino F, Wang R, Grundy SL, et al: Olanzapine versus placebo in the treatment of acute mania. Olanzapine HGEH Study Group. Am J Psychiatry. 1999, 156: 702-709.","journal-title":"Am J Psychiatry"},{"key":"227_CR25","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1097\/00004850-199911000-00003","volume":"14","author":"M Berk","year":"1999","unstructured":"Berk M, Ichim L, Brook S: Olanzapine compared to lithium in mania: a double-blind randomized controlled trial. Int Clin Psychopharmacol. 1999, 14: 339-343. 10.1097\/00004850-199911000-00003.","journal-title":"Int Clin Psychopharmacol"},{"key":"227_CR26","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1001\/archpsyc.57.9.841","volume":"57","author":"M Tohen","year":"2000","unstructured":"Tohen M, Jacobs TG, Grundy SL, McElroy SL, Banov MC, Janicak PG, Sanger T, Risser R, Zhang F, Toma V, et al: Efficacy of olanzapine in acute bipolar mania: a double-blind, placebo-controlled study. The Olanzipine HGGW Study Group. Arch Gen Psychiatry. 2000, 57: 841-849. 10.1001\/archpsyc.57.9.841.","journal-title":"Arch Gen Psychiatry"},{"key":"227_CR27","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1176\/appi.ajp.159.6.1011","volume":"159","author":"M Tohen","year":"2002","unstructured":"Tohen M, Baker RW, Altshuler LL, Zarate CA, Suppes T, Ketter TA, Milton DR, Risser R, Gilmore JA, Breier A, et al: Olanzapine versus divalproex in the treatment of acute mania. Am J Psychiatry. 2002, 159: 1011-1017. 10.1176\/appi.ajp.159.6.1011.","journal-title":"Am J Psychiatry"},{"key":"227_CR28","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1176\/appi.ajp.161.6.1057","volume":"161","author":"RM Hirschfeld","year":"2004","unstructured":"Hirschfeld RM, Keck PE, Kramer M, Karcher K, Canuso C, Eerdekens M, Grossman F: Rapid antimanic effect of risperidone monotherapy: a 3-week multicenter, double-blind, placebo-controlled trial. Am J Psychiatry. 2004, 161: 1057-1065. 10.1176\/appi.ajp.161.6.1057.","journal-title":"Am J Psychiatry"},{"key":"227_CR29","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1192\/bjp.182.2.141","volume":"182","author":"LN Yatham","year":"2003","unstructured":"Yatham LN, Grossman F, Augustyns I, Vieta E, Ravindran A: Mood stabilisers plus risperidone or placebo in the treatment of acute mania. International, double-blind, randomised controlled trial. Br J Psychiatry. 2003, 182: 141-147. 10.1192\/bjp.182.2.141.","journal-title":"Br J Psychiatry"},{"key":"227_CR30","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1176\/appi.ajp.159.7.1146","volume":"159","author":"GS Sachs","year":"2002","unstructured":"Sachs GS, Grossman F, Ghaemi SN, Okamoto A, Bowden CL: Combination of a mood stabilizer with risperidone or haloperidol for treatment of acute mania: a double-blind, placebo-controlled comparison of efficacy and safety. Am J Psychiatry. 2002, 159: 1146-1154. 10.1176\/appi.ajp.159.7.1146.","journal-title":"Am J Psychiatry"},{"key":"227_CR31","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1111\/j.1399-5618.2004.00115.x","volume":"6","author":"G Sachs","year":"2004","unstructured":"Sachs G, Chengappa KN, Suppes T, Mullen JA, Brecher M, Devine NA, Sweitzer DE: Quetiapine with lithium or divalproex for the treatment of bipolar mania: a randomized, double-blind, placebo-controlled study. Bipolar Disord. 2004, 6: 213-223. 10.1111\/j.1399-5618.2004.00115.x.","journal-title":"Bipolar Disord"},{"key":"227_CR32","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1097\/01.jcp.0000144887.66319.2f","volume":"24","author":"LN Yatham","year":"2004","unstructured":"Yatham LN, Paulsson B, Mullen J, Vagero AM: Quetiapine versus placebo in combination with lithium or divalproex for the treatment of bipolar mania. J Clin Psychopharmacol. 2004, 24: 599-606. 10.1097\/01.jcp.0000144887.66319.2f.","journal-title":"J Clin Psychopharmacol"},{"key":"227_CR33","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1176\/appi.ajp.160.4.741","volume":"160","author":"PE Keck Jr","year":"2003","unstructured":"Keck PE, Versiani M, Potkin S, West SA, Giller E, Ice K: Ziprasidone in the treatment of acute bipolar mania: a three-week, placebo-controlled, double-blind, randomized trial. Am J Psychiatry. 2003, 160: 741-748. 10.1176\/appi.ajp.160.4.741.","journal-title":"Am J Psychiatry"},{"key":"227_CR34","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.1176\/appi.ajp.160.9.1651","volume":"160","author":"PE Keck Jr","year":"2003","unstructured":"Keck PE, Marcus R, Tourkodimitris S, Ali M, Liebeskind A, Saha A, Ingenito G: A placebo-controlled, double-blind study of the efficacy and safety of aripiprazole in patients with acute bipolar mania. Am J Psychiatry. 2003, 160: 1651-1658. 10.1176\/appi.ajp.160.9.1651.","journal-title":"Am J Psychiatry"},{"key":"227_CR35","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1097\/01.jcp.0000169068.34322.70","volume":"25","author":"SG Potkin","year":"2005","unstructured":"Potkin SG, Keck PE, Segal S, Ice K, English P: Ziprasidone in acute bipolar mania: a 21-day randomized, double-blind, placebo-controlled replication trial. J Clin Psychopharmacol. 2005, 25: 301-310. 10.1097\/01.jcp.0000169068.34322.70.","journal-title":"J Clin Psychopharmacol"},{"key":"227_CR36","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1192\/bjp.187.3.229","volume":"187","author":"S Khanna","year":"2005","unstructured":"Khanna S, Vieta E, Lyons B, Grossman F, Eerdekens M, Kramer M: Risperidone in the treatment of acute mania: double-blind, placebo-controlled study. Br J Psychiatry. 2005, 187: 229-234. 10.1192\/bjp.187.3.229.","journal-title":"Br J Psychiatry"},{"key":"227_CR37","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.euroneuro.2004.06.003","volume":"15","author":"AB Smulevich","year":"2005","unstructured":"Smulevich AB, Khanna S, Eerdekens M, Karcher K, Kramer M, Grossman F: Acute and continuation risperidone monotherapy in bipolar mania: a 3-week placebo-controlled trial followed by a 9-week double-blind trial of risperidone and haloperidol. Eur Neuropsychopharmacol. 2005, 15: 75-84. 10.1016\/j.euroneuro.2004.06.003.","journal-title":"Eur Neuropsychopharmacol"},{"key":"227_CR38","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1177\/0269881106059693","volume":"20","author":"G Sachs","year":"2006","unstructured":"Sachs G, Sanchez R, Marcus R, Stock E, McQuade R, Carson W, Abou-Gharbia N, Impellizzeri C, Kaplita S, Rollin L, Iwamoto T, Aripiprazole Study Group: Aripiprazole in the treatment of acute manic or mixed episodes in patients with bipolar I disorder: a 3-week placebo-controlled study. J Psychopharmacol. 2006, 20: 536-546. 10.1177\/0269881106059693.","journal-title":"J Psychopharmacol"},{"key":"227_CR39","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1001\/archpsyc.59.1.62","volume":"59","author":"M Tohen","year":"2002","unstructured":"Tohen M, Chengappa KN, Suppes T, Zarate CA, Calabrese JR, Bowden CL, Sachs GS, Kupfer DJ, Baker RW, Risser RC, et al: Efficacy of olanzapine in combination with valproate or lithium in the treatment of mania in patients partially nonresponsive to valproate or lithium monotherapy. Arch Gen Psychiatry. 2002, 59: 62-69. 10.1001\/archpsyc.59.1.62.","journal-title":"Arch Gen Psychiatry"},{"key":"227_CR40","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.4088\/JCP.v63n1210","volume":"63","author":"JM Zajecka","year":"2002","unstructured":"Zajecka JM, Weisler R, Sachs G, Swann AC, Wozniak P, Sommerville KW: A comparison of the efficacy, safety, and tolerability of divalproex sodium and olanzapine in the treatment of bipolar disorder. J Clin Psychiatry. 2002, 63: 1148-1155.","journal-title":"J Clin Psychiatry"},{"key":"227_CR41","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1001\/archpsyc.60.12.1218","volume":"60","author":"M Tohen","year":"2003","unstructured":"Tohen M, Goldberg JF, Gonzalez-Pinto Arrillaga AM, Azorin JM, Vieta E, Hardy-Bayle MC, Lawson WB, Emsley RA, Zhang F, Baker RW, et al: A 12-week, double-blind comparison of olanzapine vs haloperidol in the treatment of acute mania. Arch Gen Psychiatry. 2003, 60: 1218-1226. 10.1001\/archpsyc.60.12.1218.","journal-title":"Arch Gen Psychiatry"},{"key":"227_CR42","doi-asserted-by":"publisher","first-page":"111","DOI":"10.4088\/JCP.v66n0116","volume":"66","author":"CL Bowden","year":"2005","unstructured":"Bowden CL, Grunze H, Mullen J, Brecher M, Paulsson B, Jones M, Vagero M, Svensson K: A randomized, double-blind, placebo-controlled efficacy and safety study of quetiapine or lithium as monotherapy for mania in bipolar disorder. J Clin Psychiatry. 2005, 66: 111-121.","journal-title":"J Clin Psychiatry"},{"key":"227_CR43","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1016\/j.euroneuro.2005.02.006","volume":"15","author":"RS McIntyre","year":"2005","unstructured":"McIntyre RS, Brecher M, Paulsson B, Huizar K, Mullen J: Quetiapine or haloperidol as monotherapy for bipolar mania \u2013 a 12-week, double-blind, randomised, parallel-group, placebo-controlled trial. Eur Neuropsychopharmacol. 2005, 15: 573-585. 10.1016\/j.euroneuro.2005.02.006.","journal-title":"Eur Neuropsychopharmacol"},{"key":"227_CR44","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1192\/bjp.187.3.235","volume":"187","author":"E Vieta","year":"2005","unstructured":"Vieta E, Bourin M, Sanchez R, Marcus R, Stock E, McQuade R, Carson W, Abou-Gharbia N, Swanink R, Iwamoto T: Effectiveness of aripiprazole v. haloperidol in acute bipolar mania: double-blind, randomised, comparative 12-week trial. Br J Psychiatry. 2005, 187: 235-242. 10.1192\/bjp.187.3.235.","journal-title":"Br J Psychiatry"},{"key":"227_CR45","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1176\/appi.ajp.160.7.1263","volume":"160","author":"M Tohen","year":"2003","unstructured":"Tohen M, Ketter TA, Zarate CA, Suppes T, Frye M, Altshuler L, Zajecka J, Schuh LM, Risser RC, Brown E, et al: Olanzapine versus divalproex sodium for the treatment of acute mania and maintenance of remission: a 47-week study. Am J Psychiatry. 2003, 160: 1263-1271. 10.1176\/appi.ajp.160.7.1263.","journal-title":"Am J Psychiatry"},{"key":"227_CR46","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1192\/bjp.184.4.337","volume":"184","author":"M Tohen","year":"2004","unstructured":"Tohen M, Chengappa KN, Suppes T, Baker RW, Zarate CA, Bowden CL, Sachs GS, Kupfer DJ, Ghaemi SN, Feldman PD, et al: Relapse prevention in bipolar I disorder: 18-month comparison of olanzapine plus mood stabiliser v. mood stabiliser alone. Br J Psychiatry. 2004, 184: 337-345. 10.1192\/bjp.184.4.337.","journal-title":"Br J Psychiatry"},{"key":"227_CR47","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1176\/appi.ajp.162.7.1281","volume":"162","author":"M Tohen","year":"2005","unstructured":"Tohen M, Greil W, Calabrese JR, Sachs GS, Yatham LN, Oerlinghausen BM, Koukopoulos A, Cassano GB, Grunze H, Licht RW, et al: Olanzapine versus lithium in the maintenance treatment of bipolar disorder: a 12-month, randomized, double-blind, controlled clinical trial. Am J Psychiatry. 2005, 162: 1281-1290. 10.1176\/appi.ajp.162.7.1281.","journal-title":"Am J Psychiatry"},{"key":"227_CR48","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1176\/appi.ajp.163.2.247","volume":"163","author":"M Tohen","year":"2006","unstructured":"Tohen M, Calabrese JR, Sachs GS, Banov MD, Detke HC, Risser R, Baker RW, Chou JC, Bowden CL: Randomized, placebo-controlled trial of olanzapine as maintenance therapy in patients with bipolar I disorder responding to acute treatment with olanzapine. Am J Psychiatry. 2006, 163: 247-256. 10.1176\/appi.ajp.163.2.247.","journal-title":"Am J Psychiatry"},{"key":"227_CR49","doi-asserted-by":"publisher","first-page":"626","DOI":"10.4088\/JCP.v67n0414","volume":"67","author":"PE Keck Jr","year":"2006","unstructured":"Keck PE, Calabrese JR, McQuade RD, Carson WH, Carlson BX, Rollin LM, Marcus RN, Sanchez R, Aripiprazole Study Group: A randomized, double-blind, placebo-controlled 26-week trial of aripiprazole in recently manic patients with bipolar I disorder. J Clin Psychiatry. 2006, 67: 626-37.","journal-title":"J Clin Psychiatry"},{"key":"227_CR50","doi-asserted-by":"publisher","first-page":"e124","DOI":"10.1371\/journal.pmed.0020124","volume":"2","author":"JP Ioannidis","year":"2005","unstructured":"Ioannidis JP: Why most published research findings are false. PLoS Med. 2005, 2: e124-10.1371\/journal.pmed.0020124.","journal-title":"PLoS Med"},{"key":"227_CR51","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1016\/S0140-6736(98)01085-X","volume":"352","author":"D Moher","year":"1998","unstructured":"Moher D, Pham B, Jones A, Cook DJ, Jadad AR, Moher M, Tugwell P, Klassen TP: Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses?. Lancet. 1998, 352: 609-613. 10.1016\/S0140-6736(98)01085-X.","journal-title":"Lancet"},{"key":"227_CR52","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1001\/archinte.1996.00440060089011","volume":"156","author":"KS Khan","year":"1996","unstructured":"Khan KS, Daya S, Jadad A: The importance of quality of primary studies in producing unbiased systematic reviews. Arch Intern Med. 1996, 156: 661-666. 10.1001\/archinte.156.6.661.","journal-title":"Arch Intern Med"},{"key":"227_CR53","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.1001\/jama.1995.03530180050029","volume":"274","author":"KF Schulz","year":"1995","unstructured":"Schulz KF: Subverting randomization in controlled trials. JAMA. 1995, 274: 1456-1458. 10.1001\/jama.274.18.1456.","journal-title":"JAMA"},{"key":"227_CR54","doi-asserted-by":"publisher","first-page":"509","DOI":"10.4088\/JCP.v67n0401","volume":"67","author":"RH Perlis","year":"2006","unstructured":"Perlis RH, Welge JA, Vornik LA, Hirschfeld RM, Keck PE: Atypical antipsychotics in the treatment of mania: a meta-analysis of randomized, placebo-controlled trials. J Clin Psychiatry. 2006, 67: 509-516.","journal-title":"J Clin Psychiatry"},{"key":"227_CR55","first-page":"CD004040","volume":"3","author":"JM Rendell","year":"2003","unstructured":"Rendell JM, Gijsman HJ, Keck P, Goodwin GM, Geddes JR: Olanzapine alone or in combination for acute mainia. Cochrane Database Syst Rev. 2003, 3: CD004040-","journal-title":"Cochrane Database Syst Rev"},{"key":"227_CR56","first-page":"CD004043","volume":"1","author":"JM Rendell","year":"2006","unstructured":"Rendell JM, Gijsman HJ, Bauer MS, Goodwin GM, Geddes GR: Risperidone alone or in combination for acute mania. Cochrane Database Syst Rev. 2006, 1: CD004043-","journal-title":"Cochrane Database Syst Rev"},{"key":"227_CR57","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1111\/j.1600-0447.2006.00912.x","volume":"115","author":"LA Smith","year":"2007","unstructured":"Smith LA, Cornelius V, Warnock A, Tacchi MJ, Taylor D: Acute bipolar mania: a systematic review and meta-analysis of co-therapy vs. monotherapy. Acta Psychiatr Scand. 2007, 115: 12-20. 10.1111\/j.1600-0447.2006.00912.x.","journal-title":"Acta Psychiatr Scand"},{"key":"227_CR58","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1001\/archpsyc.64.4.442","volume":"64","author":"H Scherk","year":"2007","unstructured":"Scherk H, Pajonk FG, Leucht S: Second-generation antipsychotic agents in the treatment of acute mania: a systematic review and meta-analysis of randomized controlled trials. Arch Gen Psychiatry. 2007, 64: 442-455. 10.1001\/archpsyc.64.4.442.","journal-title":"Arch Gen Psychiatry"},{"key":"227_CR59","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.4088\/JCP.v66n1106","volume":"66","author":"K Gao","year":"2005","unstructured":"Gao K, Gajwani P, Elhaj O, Calabrese JR: Typical and atypical antipsychotics in bipolar depression. J Clin Psychiatry. 2005, 66: 1376-1385.","journal-title":"J Clin Psychiatry"},{"key":"227_CR60","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1080\/j.1440-1614.2005.01649.x","volume":"39","author":"DJ Muzina","year":"2005","unstructured":"Muzina DJ, Calabrese JR: Maintenance therapies in bipolar disorder: focus on randomized controlled trials. Aust N Z J Psychiatry. 2005, 39: 652-661. 10.1111\/j.1440-1614.2005.01649.x.","journal-title":"Aust N Z J Psychiatry"},{"key":"227_CR61","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/0304-3959(95)00116-6","volume":"64","author":"H McQuay","year":"1996","unstructured":"McQuay H, Carroll D, Moore A: Variation in the placebo effect in randomised controlled trials of analgesics: all is as blind as it seems. Pain. 1996, 64: 331-335. 10.1016\/0304-3959(95)00116-6.","journal-title":"Pain"},{"key":"227_CR62","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/1471-2490-2-6","volume":"2","author":"RA Moore","year":"2002","unstructured":"Moore RA, Edwards JE, McQuay HJ: Sildenafil (Viagra) for male erectile dysfunction: a meta-analysis of clinical trial reports. BMC Urol. 2002, 2: 6-10.1186\/1471-2490-2-6.","journal-title":"BMC Urol"},{"key":"227_CR63","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1016\/j.pain.2004.07.004","volume":"111","author":"JE Edwards","year":"2004","unstructured":"Edwards JE, McQuay HJ, Moore RA: Efficacy and safety of valdecoxib for treatment of osteoarthritis and rheumatoid arthritis: systematic review of randomised controlled trials. Pain. 2004, 111: 286-296. 10.1016\/j.pain.2004.07.004.","journal-title":"Pain"},{"key":"227_CR64","doi-asserted-by":"publisher","first-page":"R644","DOI":"10.1186\/ar1704","volume":"7","author":"RA Moore","year":"2005","unstructured":"Moore RA, Derry S, Makinson GT, McQuay HJ: Tolerability and adverse events in clinical trials of celecoxib in osteoarthritis and rheumatoid arthritis: systematic review and meta-analysis of information from company clinical trial reports. Arthritis Res Ther. 2005, 7: R644-65. 10.1186\/ar1704. Erratum in: Arthritis Res Ther 2006, 8:401.","journal-title":"Arthritis Res Ther"},{"key":"227_CR65","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1111\/j.1399-5618.2004.00171.x","volume":"7","author":"KN Chengappa","year":"2005","unstructured":"Chengappa KN, Hennen J, Baldessarini RJ, Kupfer DJ, Yatham LN, Gershon S, Baker RW, Tohen M: Recovery and functional outcomes following olanzapine treatment for bipolar I mania. Bipolar Disord. 2005, 7: 68-76. 10.1111\/j.1399-5618.2004.00171.x.","journal-title":"Bipolar Disord"}],"container-title":["BMC Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1471-244X-7-40\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-244X-7-40.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-244X-7-40","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-244X-7-40.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,13]],"date-time":"2023-05-13T20:30:38Z","timestamp":1684009838000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpsychiatry.biomedcentral.com\/articles\/10.1186\/1471-244X-7-40"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,8,16]]},"references-count":65,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2007,12]]}},"alternative-id":["227"],"URL":"https:\/\/doi.org\/10.1186\/1471-244x-7-40","relation":{},"ISSN":["1471-244X"],"issn-type":[{"value":"1471-244X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,8,16]]},"article-number":"40"}}